Biostar Pharmaceuticals, Inc. (BSPM)

[advalorem]

This company's accounts receivable status is "concerning" to say the least. Chinese stock or not -- and I have heard management's intention to address this issue - along with the increase in sales force, 3-new product per year goal -- at some point, investors have to consider fundamental issues.

It seems like 1999 again with how some issues are disregarded or ignored.

Having said that - the stock should double from here. Triple if Glen writes an article with Biostar mentioned. :)